ESTRELLA IMMUNOPHARMA INC ESLA 深 沪
等待开盘 12-19 09:30:00 美东时间
1.58
+0.020
+1.28%
华盛通- 最 高1.635
- 今 开1.5952
- 成交量 27.23万股
- 最 低 1.41
- 昨 收 1.56
- 总市值 5714.16万
- 52周最高 3.15
- 市盈率 静 --
- 换手率 0.75%
- 52周最低 0.7301
- 委 比 -88.00%
- 总股本 3616.56万
- 历史最高 33.00
- 量 比 1.83
- 振 幅 14.42%
- 历史最低 0.00
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Estrella Immunopharma Recommended By Independent Data Safety Monitoring Board To Advance STARLIGHT-1 Study To Phase II After Review Of Safety Data
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
12-04 21:04
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
11-04 00:23
Estrella Immunopharma Completes Second Dose Cohort In STARLIGHT-1 Phase I/II Clinical Trial Of EB103
Key Findings:The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients treated in the second dose cohort.All patients treated are considered high-risk group who are not suitable to
11-03 21:08
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Strata Skin Sciences (NASDAQ:SSKN) shares increased by 44.9% to $2.23 ...
10-15 01:06
Estrella Immunopharma Regains Nasdaq Compliance
Estrella Immunopharma ( ($ESLA) ) has provided an announcement. Estrella Immuno...
09-30 05:49
Estrella Immunopharma Appoints Jia Dengyao to Board
Estrella Immunopharma ( ($ESLA) ) has provided an announcement. On September 22...
09-27 05:48
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
08-13 00:45
Estrella Immunopharma Announces Activation Of Second Clinical Site For Ongoing STARLIGHT-1 Phase I/II Clinical Trial Evaluating EB103 In Relapsed Or Refractory B-Cell NHL Patients
Estrella Immunopharma, Inc. (NASDAQ:ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
06-05 20:05
